NCT00514995已完成2 期
Sodium Oxybate in the Treatment of Binge Eating Disorder
Lindner Center of HOPE1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- The primary outcome measure will be the weekly frequency of binge-eating episodes (binge frequency).
研究概览
简要总结
The purpose of this research study is to study the effectiveness, tolerability and safety of sodium oxybate in outpatients with binge eating disorder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients will meet DSM-IV-TR criteria for BED for at least the last 6 months, determined by the Structured Clinical Interview for DSM-IV-TR (SCID) (72) and supported by the Eating Disorder Examination (EDE) (73). These criteria are as follows:
- •Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:
- •eating, in discrete period of time (eg, within any two hour period), an amount of food that is definitely larger than most people would eat in a similar period of time under similar circumstances
- •a sense of lack of control over eating during the episode (eg, a feeling that one cannot stop eating or control what or how much one is eating)
- •The binge eating episodes are associated with at least three of the following:
- •eating much more rapidly than normal
- •eating until uncomfortably full
- •eating large amounts of food when not feeling physically hungry
- •eating alone because of being embarrassed by how much one is eating
- •feeling disgusted with oneself, depressed, or feeling very guilty after overeating
- •Marked distress regarding binge eating.
- •The binge eating occurs, on average, at least two days a week for six months.
- •Does not occur exclusively during the course of bulimia nervosa and anorexia nervosa.
- •Men or women, from the ages of 21 through 65 years.
- •Female subjects must either:
- •be incapable of pregnancy because of hysterectomy or tubal ligation.
- •if heterosexually active and capable of pregnancy, have been using an acceptable method of contraception (hormonal contraceptives, intrauterine device, spermicide and barrier or double barrier methods) for at least 1 month before study entry and agree to continue the use of one of these contraception methods for the duration of the study.
- •if sexually abstinent and capable of pregnancy, agree to continue abstinence or to use an acceptable method of birth control (either hormonal contraceptives, intrauterine device, spermicide and barrier or double barrier method) should sexual activity commence.
排除标准
- •Have a current body mass index < 18kg/m2 or > 40kg/m
- •Women who are pregnant or lactating and women of childbearing potential who are not taking adequate contraceptive measures. (All women of childbearing potential will have a negative pregnancy test before entering the study.)
- •Subjects who are displaying current clinically significant depressive symptoms, defined as a Montgomery Asberg Depression Rating Scale (MADRS) (74) > 1324, or a major depressive episode by DSM-IV-TR criteria (1).
- •Subjects who have a current or past history of clinically significant suicidality (as determined by psychiatric history, SCID interview, and MADRS suicide item #10) Subjects who have made > 1 lifetime suicide attempt and those with a MADRS suicide item score > 2 will be excluded from participation.
- •Subjects who have a lifetime history of a DSM-IV-TR diagnosis of a substance abuse or dependence disorder, except for nicotine abuse or dependence (as determined by psychiatric history, SCID interview, and urine toxicology; see below).
- •Subjects who have a lifetime history of a DSM-IV-TR psychotic disorder, bipolar disorder, or dementia.
- •Subjects who have a history of a personality disorder (eg, schizotypal, borderline, or antisocial) which might interfere with assessment or compliance with study procedures.
- •Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease which could interfere with diagnosis, assessment, or treatment of binge eating disorder with sodium oxybate. Patients should be biochemically euthyroid prior to entering the study.
- •History of obstructive sleep apnea (OBS) or receiving a high risk score for OBS on the Berlin Questionnaire (75).
- •Subjects requiring treatment with any drug which might interact adversely with or obscure the action of the study medication (e.g. stimulants, sympathomimetics, antidepressants, carbonic anhydrase inhibitors, anti-obesity drugs, drugs with CNS depressant effects).
- •Subjects who have received any psychoactive medication within one week prior to randomization.
- •Subjects who have begun and/or are receiving formal psychotherapy (cognitive behavioral therapy, interpersonal therapy, or dietary behavioral therapy) for BED or weight loss within the past 3 months.
- •Subjects previously enrolled in this study or have previously been treated with sodium oxybate.
- •Subjects who have received an experimental drug or used an experimental device within 30 days.
研究组 & 干预措施
1
Experimental
干预措施: Sodium Oxybate (Drug)
结局指标
主要结局
The primary outcome measure will be the weekly frequency of binge-eating episodes (binge frequency).
时间窗: 16 weeks
次要结局
- Secondary outcome measures will include weekly frequency of binge days; body mass index; CGI-severity scores; YBOCS-BE modified for Binge Eating scores; Eating Inventory scores; and MADRS total scores.(18 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Sodium Oxybate in Patients With Episodic and Chronic Cluster HeadacheCluster HeadacheNCT02637648Ramin Khatami60
已完成
3 期
Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With FibromyalgiaFibromyalgiaNCT00803023Jazz Pharmaceuticals129
尚未招募
不适用
Sodium Oxybate for the Treatment of Vigilance Impairment in NarcolepsyNarcolepsy10040998NL-OMON30579Academisch Medisch Centrum40
已完成
4 期
Sodium Oxybate Versus Midazolam for Comfort SedationPalliative CareNCT05085873Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer22
已完成
2 期
Acamprosate in the Treatment of Binge-Eating DisorderBinge Eating DisorderNCT00511940Lindner Center of HOPE40